Skip to main content
Sattva Neelapu on Muck Rack

Sattva Neelapu

As seen in: Nature, Wiley Online Library, Cell Press, Healio, HemOnc Today, Cancer Discovery, Texas Medical Center, Blood, ONCOLOGY journal, The ASCO Post and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sattva

Contact Sattva, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Enabling access to talicabtagene autoleucel in relapsed/refractory B-cell malignancies; multicenter real-world evidence on delivery, efficacy and safety

|
By Atharva Karulkar, Hasmukh Jain, Neeraj Sidharthan, Dinesh Bhurani, Sameer Melinkeri, Pavan Kumar Boyella, Prashant Mehta, Esha Kaul, Sanket R. Shah, Chandran Nair, Rahul Bhargava, Bhausaheb Bagal, Lingaraj Nayak, Alok Shetty, Hari Menon, Devanshi Kalra, Shalini Purwar, Nirali Shah, Terry Fry, Nitin Jain, Sattva Neelapu, Manju Sengar, Rahul Purwar, Jayachandran P. K, Rakesh Reddy Boya, Ram Abhinav, Smrithi Ravikumar, Jayashree Thorat
| Nature Verified
Abstract Talicabtagene autoleucel (tali-cel) is the first humanized CD19-directed CAR-T cell therapy approved in India for relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). Here, we integrated clinical and manufacturing operations through a centralized coordination unit (CCU) and evaluated tali-cel implementation.
Open in Who Shared Issue with article?

Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma Original

|
By Karan L. Chohan, Eduardo Edelman Saul, R. Eric Davis, Fredrick Hagemeister, Raphael Steiner, Luis Fayad, Sairah Ahmed, Alma Rodriguez, Swaminathan Iyer, Ranjit Nair, Francisco Vega, Dai Chihara, Preetesh Jain, Luis Castillo, Chijioke Nze, Fateeha Furqan, Ayushi F. Chauhan, Mark Hamilton, Jared Henderson, Anath C. Lionel, Christopher Flowers, Sattva Neelapu, Michael Green, Jason R Westin
| Nature Verified
Diffuse large B-cell lymphoma (DLBCL) represents the most common non-Hodgkin lymphoma, in which ~60–85% of patients achieve a complete response (CR) with standard frontline chemoimmunotherapy approaches [1,2,3]. Despite these promising response rates, ~40% of patients can develop relapsed or refractory disease, and significant research efforts have been devoted to improving the durability and response with frontline therapies through the incorporation of novel agents [1, 2].
Open in Who Shared View Duplicates (2) Issue with article?

Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

|
By Sattva Neelapu
| Texas Medical Center
Journal of Clinical Oncology Post-print Humans, Male, Middle Aged, Female, Immunotherapy, Adoptive, Aged, Adult, Follow-Up Studies, Antigens, CD19, Lymphoma, Non-Hodgkin, Aged, 80 and over, Receptors, Chimeric Antigen, Neoplasm Recurrence, Local, Lymphoma, Follicular, Progression-Free Survival, Biological Products yes Neelapu, Sattva S; Chavez, Julio C; Sehgal, Alison R; et al., "Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin...
Open in Who Shared Issue with article?
See all 38 licensed articles (50 Total)